Insider to sell 15,000 Kestra Medical Technologies (KMTS) stock shares

Rhea-AI Filing Summary

This Form 144 notice reports a planned sale of restricted common shares of Kestra Medical Technologies, Ltd. The seller intends to sell 15,000 common shares through Merrill Lynch on the NASDAQ, with an indicated aggregate market value of $342,023.69. The shares form part of a larger base of 58,349,053 common shares outstanding.

The securities were originally acquired on 03/07/2025 as a restricted share issuance from Kestra Medical Technologies, Ltd., granted under the issuer’s equity compensation plan. The notice also shows that Brian Webster sold 15,000 common shares on 12/29/2025 for gross proceeds of $398,847.04. By signing the notice, the seller represents that they are not aware of any undisclosed material adverse information about the company.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Shares	Merrill Lynch 225 Liberty St Floor 37 New York NY 10281	15000	342023.69	58349053	01/15/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Shares	03/07/2025	Restricted share issuance	KESTRA MEDICAL TECHNOLOGIES, LTD.			15000	03/07/2025	Granted as part of issuer equity compensation plan

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Brian Webster 3933 LAKE WASHINGTON BLVD NE SUITE 200 KIRKLAND WA 98033	Common Shares	12/29/2025	15000	398847.04

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Kestra Medical Technologies (KMTS) Form 144 filing report?

It reports a planned sale of 15,000 restricted common shares of Kestra Medical Technologies, Ltd. by an insider, with an aggregate market value of $342,023.69.

How many Kestra Medical Technologies (KMTS) shares are being proposed for sale?

The notice covers a proposed sale of 15,000 common shares of Kestra Medical Technologies, Ltd.

On which exchange and through which broker will the KMTS shares be sold?

The common shares are planned to be sold on the NASDAQ through Merrill Lynch, located at 225 Liberty St, Floor 37, New York, NY 10281.

When were the Kestra Medical Technologies (KMTS) shares originally acquired and how?

The 15,000 common shares were acquired on 03/07/2025 via a restricted share issuance from Kestra Medical Technologies, Ltd., granted as part of the issuer’s equity compensation plan.

Has the insider recently sold other Kestra Medical Technologies (KMTS) shares?

Yes. The filing shows Brian Webster sold 15,000 common shares on 12/29/2025, receiving gross proceeds of $398,847.04.

How many Kestra Medical Technologies (KMTS) shares are outstanding?

The filing lists 58,349,053 common shares outstanding for Kestra Medical Technologies, Ltd.

What representation does the seller make in this Form 144 for KMTS?

By signing, the seller represents that they do not know any material adverse information about Kestra Medical Technologies, Ltd.’s current or prospective operations that has not been publicly disclosed.